FEB 23, 2017 06:00 AM PST

Obtaining Samples for Precision Medicine Studies: An Outsider's Perspective

2 2 182

  • Chief Commercial Officer, Omniseq
      Matt Klusas serves as Chief Commercial Officer at OmniSeq. He leads the OmniSeq sales, marketing, business development, and customer service functions. Prior to joining OmniSeq, Matt was most recently at Thermo Fisher Scientific, where he led a business focusing on large scale deployments of genetic analysis technologies, including next generation DNA sequencing, Capillary Electrophoresis sequencing, qPCR, and other technologies. Prior to Thermo Fisher Scientific, Matt held management roles at the American Type Culture Collection (ATCC), Life Technologies, and McKinsey & Co. Matt is published in the Journal of Commercial Biotechnology, the McKinsey Quarterly, and the Credit Union Journal. In 2015, Illinois State University selected him the Young Alumni of the Year. He received an MSc in Economic History from the London School of Economics and a BS in Communication from the Illinois State University. He also studied at Magdalen College, University of Oxford.


    Best practices for developing precision medicine diagnostics can include completing a retrospective analysis.  Obtaining enough samples to have a statistically significant study typically requires going beyond an initial institution.  There are a multitude of impediments that can frustrate the ability to rapidly identify and obtain samples.  This presentation will review these impediments by segmenting institutions into three segments: major academic medical centers, biobanks, community practices and mid-tier cancer centers.  Within each of these segments, the presentation will discuss the typical impediments.  The presentation will close with some recommendations for improving the process for both requestors and providers.      

    Show Resources
    Loading Comments...